4.16
-0.24%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beihai Gofar Chuanshan Biological Co
Its shares trade on Shanghai under the ticker 600538.SS. It has been listed since 14 January 2003. In the fiscal year to 31 December 2025, it reported revenue of CN¥328.2m and a net loss of CN¥87.6m. At that date it held total assets of CN¥896.8m and shareholders' equity of CN¥687.8m.
Beihai Gofar Chuanshan Biological Co., Ltd. The company is headquartered in Beihai, Guangxi. The company went IPO on 2003-01-14. The firm is mainly engaged in the Pharmaceutical Distribution segment, the Pharmaceutical Manufacturing segment, the Deoxyribonucleic Acid Identification and Service segment, and the Other segment. The firm is mainly engaged in pharmaceutical manufacturing and pharmaceutical distribution industries, molecular medical imaging centers, tumor radiotherapy centers, and tumor telemedicine technical services, molecular diagnostics and judicial identification technical services. The firm mainly sells its products in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 14 Jan 2003
- Employees
- 501
- Website
- gofar.com.cn ↗
Leadership
Pay as last reported
- Mr. Ye JiangChairman of the Board, since 2024
- Zhibo YinChief Financial Officer, Vice President, Director, since 2010CN¥455,800
- Mr. Yongwei LiVice President, Secretary of the Board, Director, since 2001CN¥326,500
- Xinghao HeVice PresidentCN¥14,200
- Xiaoshan HuDirectorCN¥252,900
- Di JinDirectorCN¥205,500
- Mr. Xiaowei ZhangDirector
- Fengjiao ChenIndependent DirectorCN¥60,000
- Xu HanIndependent DirectorCN¥90,000
- Xue HanIndependent DirectorCN¥30,000
- Yuqi HouIndependent DirectorCN¥90,000
- Mr. Zeyang XuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beihai Gofar Chuanshan Biological Co Ltd employs 501 full-time employees in Guangxi.
- The company's pharmaceutical manufacturing segment serves domestic markets effectively.
- Deoxyribonucleic Acid Identification services are a key focus area for the firm.
Weaknesses
- The firm's pharmaceutical distribution segment faces domestic market limitations.
- Molecular medical imaging centers require significant capital investment.
- Tumor radiotherapy centers operate within a narrow domestic market segment.
Opportunities
- Expanding molecular diagnostics services domestically could increase market share.
- Growth in judicial identification technical services offers new revenue streams.
- Tumor telemedicine technical services can reach more domestic patients.
Threats
- Competition in pharmaceutical manufacturing may reduce profit margins.
- Regulatory changes in the domestic pharmaceutical sector pose risks.
- Dependence on domestic market limits international expansion opportunities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.